ID   CHO FIX.1F
AC   CVCL_E4JT
SY   FIX.1F
RX   DOI=10.1007/978-94-017-0926-2_3;
RX   PubMed=9565160;
CC   Biotechnology: Produces recombinant human factor IX sold under the brand name of BeneFIX.
CC   Sequence variation: Gene deletion; UniProtKB; Q2MH30; Dhfr; Zygosity=Heterozygous (from parent cell line).
CC   Sequence variation: Mutation; UniProtKB; Q2MH30; Dhfr; Simple; p.Thr137Arg (c.410G>C); Zygosity=Heterozygous (from parent cell line).
CC   Genetic integration: Method=Transfection; Gene=HGNC; HGNC:3551; F9.
CC   Genetic integration: Method=Transfection; Gene=HGNC; HGNC:8568; FURIN (Note=Soluble version).
CC   Genetic integration: Method=Transfection; Gene=MGI; MGI:94890; Dhfr.
CC   Genetic integration: Method=Transfection; Gene=UniProtKB; P00552; Transposon Tn5 neo.
CC   Transformant: ChEBI; CHEBI_23994; Ethyl methanesulfonate (Methylsulfonic acid ethyl ester; MSEE).
CC   Transformant: NCIt; C44386; Gamma radiation.
CC   Derived from site: In situ; Ovary; UBERON=UBERON_0000992.
CC   Cell type: Epithelial cell of ovary; CL=CL_2000064.
OX   NCBI_TaxID=10029; ! Cricetulus griseus (Chinese hamster)
HI   CVCL_1977 ! CHO-DXB11
SX   Female
AG   Adult
CA   Transformed cell line
DT   Created: 19-12-24; Last updated: 19-12-24; Version: 1
//
RX   DOI=10.1007/978-94-017-0926-2_3;
RA   Edwards J.B., Kirby N.;
RT   "Recombinant coagulation factor IX (BeneFIX).";
RL   (In book chapter) Biopharmaceuticals, an industrial perspective; Walsh G., Murphy B. (eds.); pp.73-108; Springer; Dordrecht; Germany (1999).
//
RX   PubMed=9565160;
RA   Harrison S., Adamson S.R., Bonam D., Brodeur S., Charlebois T.S.,
RA   Clancy B., Costigan R.J., Drapeau D., Hamilton M.A., Hanley K.,
RA   Kelley B.D., Knight A., Leonard M.W., McCarthy M., Oakes P., Sterl K.,
RA   Switzer M., Walsh R., Foster W.B.;
RT   "The manufacturing process for recombinant factor IX.";
RL   Semin. Hematol. 35 Suppl. 2:4-10(1998).
//